5-(5-Fluoro-2-Oxo-1,2-Dihydro-Indol-3-Ylidenemethyl)-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid

Manufacturing campaigns for the malate salt derived from this indolinone-pyrrole carboxylic acid scaffold are governed by ICH Q7 active pharmaceutical ingredient GMP, with critical quality attributes anchored to Ph. Eur. monograph 2859 and USP-NF Sunitinib Malate as of the 2023 revision cycle. The free acid intermediate, received with a minimum anhydrous HPLC purity of 98.5% and a single unknown impurity threshold below 0.15%, is charged into a 2000-litre glass-lined reactor at a molar ratio of precisely 1.00 equivalent to 1.05 equivalents of L-malic acid dissolved in a tetrahydrofuran–purified water mixture (4:1 v/v) preheated to 55 ± 2 °C. The addition rate is controlled by an automated dosing skid to maintain the solution temperature within a 2 °C band, thereby suppressing premature nucleation that would yield a metastable polymorphic form identified as Type II in the patent literature. After a hold time of 90 minutes under constant 150 rpm pitched-blade agitation, the batch is cooled via a linear ramp of 0.3 °C/min to 5 °C, during which the desired Type I crystallites precipitate; inline focused-beam reflectance measurement (FBRM) triggers a secondary hold of 60 minutes when the chord length distribution centroid reaches 35 µm. The slurry is centrifuged in a 1000 mm basket centrifuge with a 50 µm polypropylene filter cloth, washed with chilled 0.1 M aqueous L-malic acid (2 × 150 litres), and dried in a double-cone vacuum dryer at 40 °C and ≤ 10 mbar until loss-on-drying by halogen analysis stabilizes below 0.5% w/w. The dried salt is sieved through a 500 µm oscillating screen, blended with pre-gelatinized starch and mannitol in a 1200-litre bin blender, and roller-compacted to a ribbon density of 1.15 ± 0.05 g/cm³ using a 25 kN/cm compaction force before final milling through a 1.0 mm rasp screen. The final blend is filled into size 0 hard gelatin capsules to a target fill weight corresponding to a delivered dose of 50 mg sunitinib free base per capsule, with in-process uniformity verified by NIR probe integration across 100% of the compression cycle. The immediate downstream regulatory pathway submits to 21 CFR Part 210/211 finished pharmaceutical GMP and the documentation structure of ICH M4Q Common Technical Document, resulting in a finished dosage form identified as Sunitinib Malate Capsules, the reference listed drug under NDA 021938 and the product of originator oncolytic commercial manufacture.

The preceding half-century of indigo-related dyeing infrastructure does not extend to this molecule; the sole ton-scale deployment resides in pharmaceutical oncology, a sector where the geometric isomer ratio established during the pre-salt condensation step becomes the variable that separates a successful dissolution profile from a bioinequivalent lot. During the Knoevenagel-type aldol condensation between 5-fluoro-2-oxindole and 2,4-dimethyl-1H-pyrrole-3-carboxaldehyde, the Z-configuration must constitute no less than 98.9% of the total isomeric population, because the E-form exhibits a 4.7-fold lower intrinsic dissolution rate in pH 1.2 simulated gastric fluid as measured by rotating-disc USP apparatus II at 100 rpm. Industrial batches are reacted in anhydrous N,N-dimethylformamide with a 5 wt% piperidine catalyst loading relative to the oxindole input, held for 48 hours at 25 ± 2 °C, then quenched into 15 volumes of purified water pre-acidified to pH 4.0 with acetic acid; the resulting amorphous precipitate is separated by vacuum filtration and dried under a nitrogen blanket at 30 °C to a water content below 0.8% by Karl Fischer titration. Pharmaceutical solid-state stability studies conducted in accordance with ICH Q1A(R2) show that the amorphous free acid undergoes a glass transition at 68 °C, imposing a hard limit of 60 °C on any post-isolation drying step and demanding that downstream reactive crystallization to the malate salt be executed within 48 hours of final drying to avoid progressive isomerization that, at 25 °C and 60% relative humidity, proceeds at a rate of approximately 0.02% (Z→E)/day. The terminal product form is once again Sunitinib Malate, but the critical distinction is the intramolecular Z-configured double bond retained through every processing step; analytical monitoring by Ph. Eur. 2.2.29 liquid chromatography with a 150 × 4.6 mm C18 column and acetonitrile–ammonium formate pH 3.5 mobile phase provides a detection limit of 0.05% for the E-stereoisomer, while the certificate of analysis specification allows a maximum of 0.10%.

What powder-rheology pitfalls appear when a generic candidate attempts a high-dose dry-granulated tablet bioequivalent to the reference capsule?

Anda-based solid oral dosage form development for the sunitinib free-acid-derived malate salt, filed under 21 CFR 314.94 with bioequivalence requirements of 90% confidence interval within 80.00–125.00% for C_max and AUC, exposes formulation fragility at API loads exceeding 55% w/w of the core tablet weight. The salt’s cohesive nature—compounded by a D₉₀ particle size that must be reduced below 15 µm by spiral jet milling with a grinding pressure of 6.5 bar and a classifier speed of 11 000 rpm—generates a powder with a compressibility index routinely above 35% and a Hausner ratio of 1.50 at the 50 µm sieve cut. In a high-shear wet-granulation route, the addition of 20 wt% aqueous ethanol to the granulating liquid at a level of 18.5% of the intragranular mass improves granule porosity, yet the local heating during tray drying at 55 °C has been observed on 3 m² fluid-bed dryers to generate minor amorphization at edges, detected as a glass transition endotherm at 62 °C in modulated DSC, which in turn accelerates recrystallization-induced agglomeration upon subsequent compression at 18 kN on a 32-station rotary press. More consistent results are obtained with a dry granulation roller compaction train equipped with a 150 mm diameter, 50 mm width corrugated rolls operating at a gap of 2.0 mm and a specific compaction force of 12 kN/cm, followed by integrated oscillating milling through a 1.25 mm screen and final blending with extragranular croscarmellose sodium (4.0% w/w) and magnesium stearate (0.75% w/w). Tablet content uniformity, evaluated by stratified sampling across 40 positions in a 120 kg bin, shows relative standard deviation falling below 3.0% only when the milled ribbons have a solid fraction between 0.65 and 0.72, as determined by envelope density measurements per USP ⟨616⟩. The final dosage form is an immediate-release film-coated tablet delivering 25 mg, 37.5 mg, or 50 mg sunitinib free base, supported by an ICH M13A-aligned fed-state pharmacokinetic study in healthy volunteers and monitored through post-approval stability protocols under ICH Q1E with bracketing based on the 50 mg strength as worst case for oxidative degradation.

Veterinary oncology introduces a parallel regulatory universe where the identical indolinone-pyrrole carboxylic acid intermediate is converted not to the malate salt but to the phosphate salt, toceranib phosphate, approved under NADA 141-295 by the FDA Center for Veterinary Medicine for the treatment of recurrent or non-resectable Patnaik grade II/III cutaneous mast cell tumors in dogs. The conversion follows a stoichiometrically comparable pathway: the free acid (1.0 equivalent) is suspended in 8 volumes of acetone–water (9:1 v/v), reacted with 1.1 equivalents of 85% phosphoric acid, heated to reflux (57 °C) for 45 minutes, and crystallized by controlled cooling over 4 hours to 0–5 °C; the collected phosphate salt is dried at 45 °C under 50 mbar to a residual acetone level below 500 ppm as measured by headspace GC per VICH GL18 residual solvent guidelines. Finished veterinary tablets are manufactured by direct compression of the phosphate salt with dicalcium phosphate dihydrate as the primary diluent, and the mixing process is qualified by blend uniformity analysis using a near-infrared probe calibrated against a partial least-squares model across a concentration range of 15–35% w/w API. The labeled dose strengths—10 mg, 15 mg, and 50 mg toceranib free base—are targeted to a body-weight-based posology of 3.25 mg/kg administered every other day, with manufacturing process validation requiring that dissolution testing per USP Apparatus II in 900 mL of pH 6.8 phosphate buffer achieve not less than 80% (Q) release at 45 minutes across 12 dosage units sampled from the beginning, middle, and end of the compression run. The veterinary-specific pharmacovigilance obligations under 21 CFR 514.80 mandate annual adverse drug experience reporting that, across 5 post-market surveillance years for the 50 mg presentation, has documented fewer than 0.4 events per 10 000 doses dispensed, a figure that must be contextualized against background comorbidities in the target canine population. The end product is Toceranib Phosphate Tablets, a polyvinyl alcohol-based film-coated scored tablet containing the same conjugated indolinone pharmacophore but differentiated from human oncolytics by salt identity, species-specific pharmacokinetics, and a distinct regulatory docket.

When a clinical combination protocol pairs this kinase inhibitor with an immune checkpoint blockade, the supply chain diverges sharply from commercial manufacturing at the level of packaging configuration and batch record granularity.

Clinical trial material for a Phase II/III open-label study evaluating sunitinib malate in combination with an anti-PD-1 monoclonal antibody is produced according to EU GMP Annex 13 for investigational medicinal products, with quality oversight extending to the Qualified Person certification requirements of Directive 2001/20/EC Article 13.3. The process uses the same API source and the same roller-compaction-based dry granulation procedure validated at the 50 mg dose, but the randomization blinding necessitates over-encapsulation of the tablet into an opaque size 0el hard gelatin capsule containing the active tablet plus a lactose monohydrate-backfilled placebo microtablet, a configuration that requires disintegration testing in both 0.1 N HCl and pH 4.5 acetate buffer to verify that gelatin shell dissolution does not delay the onset of drug release beyond 15 minutes. Blister packaging is conducted on a 450 blister-per-minute thermoforming line with a cold-form aluminium laminate cavity, achieving a moisture vapor transmission rate below 0.01 g/m²/day and an oxygen transmission rate below 0.1 cm³/m²/day·atm as tested under ASTM F1249-20 and ASTM D3985-17, respectively. The addition ratio of the indolinone-pyrrole constituent in the total investigational product remains anchored to the approved commercial formulation basis—50 mg free-acid equivalent per unit—but the batch record enumerates every manual transfer step associated with the over-encapsulation process, because EU GMP Annex 13 Section 36 requires that the primary packaging record permit reconciliation of all capsule shells and placebo components to an accuracy of 100.0%. The product is labelled with randomization code, protocol identifier, and a shelf-life of 24 months at 25 °C based on ongoing stability studies that include photostability per ICH Q1B Option 2; any excursion beyond 30 °C for more than 72 cumulative hours triggers a formal temperature excursion assessment and potential batch disqualification. The terminal output is a clinical investigation kit, not a marketed drug product, and its regulatory foundation is the Investigational Medicinal Product Dossier rather than a finalized Module 3.2.P.

Academic kinase-profiling panels and crystallographic fragment screening demand that the carboxylic acid intermediate be supplied at a level of purity that dwarfs even the pharmacopoeial monograph requirements. A lot intended for co-crystallization with the ATP-binding pocket of recombinant VEGFR-2 tyrosine kinase domain must pass an ICH Q3C-limited residual solvent analysis—dimethylformamide below 380 ppm, dichloromethane below 600 ppm—alongside a bioburden of ≤ 10 CFU/g and endotoxin below 0.5 EU/mg as determined by a kinetic chromogenic Limulus amebocyte lysate assay calibrated at 0.005 EU/mL sensitivity in accordance with USP ⟨85⟩. The compound is dissolved in DMSO-d6 to a stock concentration of 10 mM and diluted into kinase reaction buffer (25 mM HEPES pH 7.4, 10 mM MgCl₂, 0.01% Brij-35) to a final test concentration range of 0.1 nM to 10 µM; an ADP-Glo™ assay platform, read on an BMG LABTECH PHERAstar FSX with 384-well small-volume plates, yields an IC₅₀ of 4 nM against the VEGFR-2 construct, a value that shifts to 15 nM if the DMSO carrier exceeds 0.2% v/v due to solvent-induced conformational drift in the DFG-loop. In a crystallization drop of 200 nL compound solution (2 mM in 20% PEG 3350, 0.2 M ammonium acetate, 0.1 M Tris pH 8.2) combined with 200 nL protein solution (8 mg/mL unphosphorylated KDR kinase domain), stacked plate-shaped crystals of the co-complex diffracting to 1.7 Å resolution at a synchrotron beamline under cryoconditions with 25% glycerol as cryoprotectant allow unambiguous placement of the indolinone carbonyl oxygen as a hinge-region hydrogen-bond acceptor to the backbone NH of Cys⁹¹⁹. The scale of operation is the 100-gram research lot rather than the multi-hundred-kilogram commercial campaign, and the packaging is a 50 mL amber borosilicate glass vial sealed under argon with a PTFE-lined septum, accompanied by a certificate of analysis complying with ISO/IEC 17025:2017 for the assay, water content, and purity parameters. The finished product type is a “research-grade kinase inhibitor probe,” stored at −20 ± 5 °C and shipped with a calibrated temperature data logger to maintain a cold chain record; failure to maintain the temperature requirement during transit invalidates the stability guarantee and renders the lot unsuitable for quantitative SAR studies.

Between the human oncology suite and the complementary veterinary approval lies a quality standard bifurcation that deserves a tabular synthesis, because the same indolinone-pyrrole free acid becomes subject to divergent impurity thresholds and analytical methodologies that directly impact the choice of downstream salt formation and packaging configuration. The values collected below reflect current compendial and regulatory filing positions for the 50 mg strength, and the reader should note that crystallographic purity terminology for the Z-isomer is defined as area percentage relative to the combined Z plus E peak areas by the HPLC method of Pharmacopoeia Europe 2.2.29.